The First Trimester Gravid Serum Regulates Procalcitonin Expression in Human Macrophages Skewing Their PhenotypeIn Vitro

Mediators of Inflammation - Tập 2014 - Trang 1-10 - 2014
Damiano Rami1, Martina La Bianca1, Chiara Agostinis2, Giorgio Zauli2, Oriano Radillo2, Roberta Bulla1
1Department of Life Sciences, University of Trieste, via Valerio 28, 34127 Trieste, Italy
2Institute for Maternal and Child Health, IRCCS Burlo Garofolo, 34137 Trieste, Italy

Tóm tắt

Procalcitonin (PCT) is one of the best diagnostic and prognostic markers in clinical practice, widely used to evaluate the evolution of bacterial infections. Although it is mainly produced by thyroid, during sepsis almost all the peripheral tissues are involved in PCT production. Parenchymal cells have been suggested as the main source of PCT expression; however the contribution of macrophages is not clear yet. In response to environmental cues, tissue macrophages acquire distinct functional phenotypes, ranging from proinflammatory (M1) to anti-inflammatory (M2) phenotype. Macrophages at the fetal-maternal interface show immunosuppressive M2-like activities required for the maintenance of immunological homeostasis during pregnancy. This study aims to clarify the ability to synthesise PCT of fully differentiated (M0), polarized (M1/M2) macrophages and those cultured either in the presence of first trimester gravid serum (GS) or pregnancy hormones. We found out that M1 macrophages upregulate PCT expression following LPS stimulation compared to M0 and M2. The GS downregulates PCT expression in macrophages, skewing them towards an M2-like phenotype. This effect seems only partially mediated by the hormonalmilieu. Our findings strengthen the key role of macrophages in counteracting inflammatory stimuli during pregnancy, suggesting PCT as a possible new marker of M1-like macrophages.

Từ khóa


Tài liệu tham khảo

10.1007/s00011-012-0439-5

10.1038/304129a0

10.1111/j.1476-5381.2009.00433.x

10.1128/JCM.00655-10

2001, The Journal of Clinical Endocrinology & Metabolism, 86, 396

2001, Shock, 16, 109, 10.1097/00024382-200116020-00004

10.1210/en.2003-0854

10.1097/01.CCM.0000134404.63292.71

10.1210/jc.79.6.1605

10.1016/S0165-2478(02)00158-X

10.1016/S0022-2143(99)90053-7

10.1093/cid/cir050

2012

10.1038/nri2528

10.1038/nri2784

10.1016/j.immuni.2005.10.001

10.1002/eji.200636910

10.1172/JCI59643

10.1177/1933719109349962

10.3389/fimmu.2012.00055

10.1186/1471-2180-12-68

10.4049/jimmunol.1000413

10.4049/jimmunol.1100130

10.1016/j.molimm.2007.12.025

2008, Gene Therapy and Molecular Biology, 12, 15

10.1016/j.jim.2011.10.013

10.1111/j.0300-9475.2005.01545.x

10.1016/j.cellimm.2013.06.012

10.1016/j.jri.2013.07.001

10.1111/j.1600-0897.2010.00836.x

10.1111/j.1365-2249.2011.04330.x